

Synthesis of a Potential Intermediate for TMC-95A via an Organocatalyzed Aldol Reaction

Anthony J. Pearson,*^{,†} Santanu Panda,[†] and Scott D. Bunge[‡]

[†]Department of Chemistry, Case Western Reserve University, Cleveland, Ohio 44106, United States

[‡]Department of Chemistry, Kent State University, Kent, Ohio 44242, United States

Supporting Information



ABSTRACT: *N*-Prolinylanthranilamide-based pseudopeptide organocatalyst **14** was shown to promote enantioselective direct aldol reaction of 7-iodoisatin and 2,2-dimethyl-1,3-dioxan-5-one with 90% conversion (75% isolated yield), 90% enantioselectivity, and 23:1 diastereoselectivity. To demonstrate the synthetic utility of this chemistry, the racemic aldol reaction product was converted in five steps to a potential intermediate for construction of the natural product TMC-95A.

INTRODUCTION

Given the widespread occurrence in nature of aldol-derived organic compounds, it is not surprising that the development of methods for asymmetric aldol reactions has occupied a prominent place in modern synthetic organic chemistry. In recent years, the emergence of organocatalysts for asymmetric aldol reactions has attracted the attention of numerous researchers.¹ The aldol reaction between isatins and ketones generates 3-substituted 3-hydroxyoxindoles, which are versatile building blocks for many natural products² and drug candidates such as TMC-95A-D,³ convolutamydines,⁴ celogentin K,⁵ maremycin B,⁶ and others. TMC-95A and TMC-95B (Figure 1) represent a new class of powerful reversible proteasome inhibitors,^{3a} the total syntheses of which have been reported by several groups.⁷ Inoue et al. reported the total synthesis of TMC-95A in 29 steps via intermediate 2, which was prepared in 13 steps (Scheme 1A).^{7c} The efficiency of this synthesis can be improved by securing a shorter route to 2 or similar



Figure 1. Structures of TMC-95A-D.

intermediate, for example, via asymmetric aldol chemistry, recognizing that the protected amine group can be constructed by appropriate manipulation of the carbonyl group of a ketone such as 3 (Scheme 1B).

RESULTS AND DISCUSSION

The β -hydroxy carbonyl compound 3 might be secured by aldol reaction of 7-iodoisatin (4) and 2,2-dimethyl-1,3-dioxan-5-one (6). For the present study, we used this ketone instead of 2-(4-methoxyphenyl)-1,3-dioxan-5-one (required for 2) since it is commercially available and has a diol protecting group that can be removed using similar conditions. In addition, a PMP acetal would produce an extra stereogenic center from the aldol reaction, further complicating product mixture characterization. This paper describes our efforts to identify a catalyst for highly enantioselective and diastereoselective synthesis of compound 3 and its conversion to intermediate 5.

We investigated a selection of organocatalysts (Figure 2, Table 1) for the direct asymmetric aldol reaction between 7iodoisatin and the protected 1,3-dihydroxyacetone. The major product in each case was the desired compound 3, having two new contiguous stereocenters, one of which is tertiary. To ensure that the correct diastereomer would be produced by the aldol reaction, the relative stereochemistry of this compound was established by X-ray crystal structure determination of racemic material prior to embarking on studies of the asymmetric aldol reaction (see Supporting Information for details and ORTEP plot).

Received: August 7, 2013 Published: September 11, 2013

Scheme 1

(A) Synthesis of TMC 95A by Inoue et al.





Figure 2. Catalysts investigated for the aldol reaction of 7-iodoisatin (4) with 2,2-dimethyl-1,3-dioxan-5-one (6).

The CD spectrum of nonracemic **3** showed a negative Cotton effect at around 220–260 nm, which is similar to the CD spectra of oxindole natural products that have the same stereochemistry at the 7-position.⁸ In addition, we have shown that catalyst **8** promotes the aldol reaction of acetone with substituted isatins by addition at the *si* face of the isatin carbonyl, as required for 3.^{9a} Asymmetric aldol reactions of isatins and cyclohexanone using nonproline-based organo-catalysts have previously been reported, ¹⁰ but as far as we are aware, similar reactions with **6** have not been studied.

N-Prolinylanthranilamide pseudopeptides 7 and 8 have been reported by us to be effective organocatalysts for the aldol reactions of isatins and acetone to afford 3-substituted 3hydroxyoxindoles.9 Accordingly, these compounds were screened for the aldol reaction shown in Figure 1B. In addition to 7 and 8, we screened L-proline, L-valine, and other known catalysts, such as tetrazoles 9¹¹ and 10,¹² diamine 11,¹³ and sulfonamide 12.14 Initially, we employed the optimized conditions that were developed in our earlier work for 7 and 8.96 Both L-proline and L-valine were ineffective under these conditions (Table 1, entries 1 and 2). Catalyst 8 gave better enantio- and diastereoselectivity than 7 (Table 1, entry 4 vs 3), illustrating the beneficial effect of 6-methyl substitution in the anthranilic acid core as previously observed,9 but the conversion was still low. By using tetrazoles 9 and 10, the enantioselectivity was improved compared to 8, again with low conversion (entries 5 and 6). Also, there was very poor conversion using catalysts 11 and 12 (entries 7 and 8). Proline

tetrazole (9) has been reported in the literature for aldol reaction of isatins and isobutyraldehyde using isopropyl alcohol as the solvent and H_3PO_4 as an additive.¹⁵ Good conversion and diastereoselectivity were obtained for the present reaction using 9 in isopropyl alcohol and using TFA and water as additives, but the ee was low compared to the reaction in DMSO (entry 9 vs 5). By using 30 mol % H_3PO_4 (relative to 7-iodoisatin) in isopropyl alcohol, maintaining water as previously used the reaction ran to completion in 24 h and gave good ee and dr (entry 10). Catalyst 10 also afforded complete conversion and good ee and dr under these conditions. Increased reaction rate, but poor selectivity was observed for catalyst 11 under these conditions (entry 13), while 12 gave increased rate with good stereoselectivity (entry 14).

The marked improvement observed upon using amino tetrazoles versus the corresponding amino acids (Table 1, entry 10 vs 1 and 11 vs 2) prompted us to replace the carboxyl group of our catalysts with a tetrazole moiety. Catalysts 13 and 14, being the tetrazole analogues of 7 and 8, would test the effect of 6-methyl substitution in the anthranilic acid core, while a comparison of 15 with 14 would confirm that the tetrazole unit in the absence of the secondary amine is ineffective (the accepted mechanism requiring formation of an enamine from the latter moiety). By using catalyst 14, the reaction afforded 90% ee and 23:1 diastereoselectivity at 90% conversion (Table 1, entry 17). The reaction was much slower (5-6 days)compared to proline tetrazole (Table 1, entry 10, reaction completed in 24 h), as well as catalyst 8 (3 days), but the diastereo- and enantioselectivity were much higher. By using catalyst 13, the enantiomeric excess and diastereoselectivity were both lower compared to catalyst 14, which again confirms the beneficial effect of introducing the 6-methyl group noted in our earlier work (entry 17 vs 15), the improvement being comparable to that observed with the corresponding carboxylic acid derivatives (compare with entry 4 vs 3). There was no conversion using catalyst 15, which indicates that the secondary amine is essential for the aldol transformation, as expected (entry 18). The slower reactivity of 13 and 14, compared to that of simpler amino acid tetrazoles, is likely due to increased steric hindrance at the structural units that are responsible for activity, in particular, the proline amino group. Anthranilamides of this type show an intramolecular hydrogen bonding between the anilide NH and neighboring CO, which was reported by us^{9b} and other groups (Figure 3).¹⁶ We previously suggested that this favors a conformation that places the secondary amine

		20 mol% catalyst Solvent, additive, H₂O 4 °C, 3-6 days	$\begin{array}{c} 0 \\ H0 \\ H0 \\ H0 \\ H \\ H \\ H \\ H \\ H \\ $	=0
entry ^a	catalyst	solvent, additive	conversion $(\%)^b$	syn/anti, ee (%) ^c
1	L-pro	DMSO, TFA	<5	ND
2	L-val	DMSO, TFA	<5	ND
3	7	DMSO, TFA	18	5:1, 65
4	8	DMSO, TFA	25	7:1, 72
5	9	DMSO, TFA	20	4:1, 80
6	10	DMSO, TFA	20	4:1, 78
7	11	DMSO, TFA	<5	ND
8	12	DMSO, TFA	<5	ND
9	9	<i>i</i> -PrOH, TFA	60	15:1, 64
10^d	9	<i>i</i> -PrOH, H ₃ PO ₄	100	17:1, 68
11^d	10	<i>i</i> -PrOH, H ₃ PO ₄	100	19:1, 69
12^d	8	<i>i</i> -PrOH, H ₃ PO ₄	80	17:1, 58
13^d	11	<i>i</i> -PrOH, H ₃ PO ₄	70	4:1, 5
14^d	12	<i>i</i> -PrOH, H ₃ PO ₄	40	16:1, 63
15^d	13	<i>i</i> -PrOH, H ₃ PO ₄	90	19:1, 84
16	14	DMSO, TFA	<10	ND
17^d	14	<i>i</i> -PrOH, H ₃ PO ₄	90	23:1, 90
18^d	15	<i>i</i> -PrOH, H ₃ PO ₄	0	ND

Table 1. Optimization of Organocatalytic Aldol Reaction of 7-Iodoisatin and 2,2-Dimethyl-1,3-dioxan-5-one

^aUnless specified otherwise, the concentration of 7-iodoisatin is 0.20 M, and 2,2-dimethyl-1,3-dioxan-5-one/DMSO is 0.8 M, 550 mol % of water, 10 mol % of TFA; the reactions were run at 4 °C. Volume of DMSO = 0.4 mL. Reaction time = 72 h. ^bPercent conversion was determined from the HPLC of the crude reaction mixture. ^CDiastereoselectivity and enantiomeric excess were determined by HPLC using CHIRALPAK AD-H column. ^dUnless specified otherwise, the concentration of 7-iodoisatin is 0.20 M, and 2,2-dimethyl-1,3-dioxan-5-one/isopropyl alcohol is 0.80 M, 550 mol % of water, 30 mol % of H₃PO₄; the reactions were run at 4 °C. Volume of isopropyl alcohol = 0.1 mL. Reaction time = 24-144 h.



Figure 3. Intramolecular hydrogen bonding for N-acylanthranilamides (dashed line).

and carboxylic acid moieties in close proximity, as required for promoting the aldol reaction. Variable-temperature ¹H NMR studies with catalyst 14 confirmed the same hydrogen bonding interaction for this compound. A temperature coefficient ($\Delta\delta$ / ΔT) of 2.4 ppb/K for 14 compared to 7 (4.6 ppb/K) indicates that 14 has significantly stronger hydrogen bonding and suggests a greater preference for the "reverse turn" conformation that influences its catalytic competency.

After obtaining good ee with 7-iodoisatin, catalyst 14 was screened for reactions of other isatins (Figure 4). By using 7chloroisatin, there was a drop in ee and dr. Substitution did not appear to adversely impact reactivity. The aldol reactions of 5bromo-, 6-bromo-, and 4-bromoisatin afforded good yield, dr, and ee. We do not have a rational explanation for the observed variations in diastereoselectivity using these different substrates.

Concurrent with our studies on the aldol reaction, we investigated methods for the further conversion of 3 to the TMC-95A intermediate 5, using racemic material for a more expedient evaluation of our strategy. The most direct approach



Figure 4. Products from aldol reactions of substituted isatins and 2,2dimethyl-1,3-dioxan-5-one.

would be a stereocontrolled reductive amination of 3. In order to test the feasibility of enlisting the tertiary 7-hydroxyl as a directing group for this type of transformation, we carried out model studies on reduction of the carbonyl group of 3 using different reagents. Hydroxyl-directed reduction using NaBH- $(OAc)_3/AcOH$ at -10 °C, as developed by Evans,¹⁷ afforded the anti-1,3-diol 22 with excellent selectivity. In contrast, the



syn-1,3-diol **21** was obtained by steric approach control using NaBH₄/MeOH (Scheme 2). The small coupling constant (J = 1.6 Hz) between H9 and H10 (numbering as for 3, Scheme 1) for **21** confirms their *syn* (axial/equatorial) relationship, compared to the greater diaxial coupling for **22** (J = 9.2 Hz).

This result prompted us to examine the possibility of a hydroxy-directed reductive amination¹⁸ to produce intermediate 23a (NHBn replacing NHCbz of 5). Attempted direct reductive amination using benzylamine combined with NaBH- $(OAc)_3$ afforded alcohol 22 instead of the amine, indicating that ketone reduction outpaces imine formation/reduction. Various methods for reduction of the preformed imine,^{18a} oxime, oximino benzyl ether,^{18b} or oximino benzoyl ester also did not afford the desired product. We were eventually able to prepare intermediate 23, but as an equimolar mixture of epimers (a) and (b) in 42% yield by reaction of 3 with benzylamine/AcOH in DCM in the presence of molecular sieves, followed by in situ treatment of the resulting imine with NaBH₃CN at 2 °C. While the formation of this equimolar mixture is somewhat disappointing, it does suggest some hydroxyl participation during the reduction (which would result in 23a), given the observation that steric approach control during reduction of 3 gives a single diastereomer analogous to 23b. Unfortunately, the desired isomer 23a could not be obtained pure from the mixture of epimers. In view of the technical difficulties and poor stereocontrol encountered with

the reductive amination of 3, we elected to use a somewhat longer but more reliable sequence for the synthesis of 5^{19} .

Article

The alcohol 3 reacted smoothly with TMSOTf to afford 24 in greater than 80% yield. Borohydride reduction of the carbonyl group followed by conversion of the resulting secondary alcohol to mesylate 25 proceeded in good yield (preparation of the mesylate without prior tertiary hydroxyl protection was problematic). The mesylate underwent S_N2 reaction with an azide ion to furnish 26 by using NaN₃/18-crown-6 in DMF at 100 °C, which proceeded with concomitant removal of the TMS group. After screening a variety of reaction conditions, azide 26 was successfully converted to the Cbz-protected amine 5 in 69% yield in one step using PMe₃/CbzCl.

CONCLUSIONS

In summary, the aldol reaction of 7-iodoisatin with 2,2dimethyl-1,3-dioxan-5-one catalyzed by the *N*-prolinylanthranilamide-based pseudopeptide 14 afforded the aldol product 3 in high yield and excellent stereoselectivity. While we were able to synthesize intermediate 23 (NHBn instead of NHCbz) by reductive amination of 3 in a one-pot, two-step operation, this reaction suffered from poor stereoselectivity and low yield. Compound 3 was more efficiently converted to the potential TMC-95A intermediate 5 over five steps in 25% overall yield. We are confident that an identical asymmetric aldol strategy can be used to secure compound 2, which is a known





intermediate for TMC-95A synthesis and differs from 5 only in the nature of its 1,3-diol protection.

EXPERIMENTAL SECTION

General Methods. All reactions were performed with anhydrous solvents in oven-dried and argon-charged glassware unless otherwise stated. All solvents were freshly distilled before use. Analytical thin layer chromatography was carried out using glass bedded silica gel 60 F 254, 0.25 mm thickness. Flash chromatography was carried out on silica gel 60 Å (230–400 mesh). ¹H NMR and ¹³C NMR spectra were recorded on a 400 or 600 MHz spectrometer (operating frequency refers to ¹H) and are internally referenced to residual solvent signals. High-resolution mass spectra were recorded using a magnetic sector mass analyzer.

For the synthesis of catalysts 13 and 14 (Scheme 3), experimental details are given for the synthesis of 14, and characterization data only are listed for compounds leading to 13, the procedures being identical. (S)-tert-Butyl (1-(1-Benzyl-1H-tetrazol-5-yl)-2-methylpropyl)*carbamate* (**28**). To a stirred solution of (S)-*tert*-butyl (2-methyl-1-(1*H*-tetrazol-5-yl)propyl)carbamate (**27**)²⁰ (400 mg, 1.65 mmol) in dry DMF (6 mL) was added potassium carbonate (343 mg, 2.5 mmol) followed by benzyl bromide (0.4 mL, 3.3 mmol). The reaction mixture was stirred at rt for 24 h and monitored by TLC. After completion of the reaction, the mixture was quenched with water and the product was extracted with ethyl acetate, dried over Na₂SO₄, and concentrated in vacuum. Flash chromatography (hexanes/ethyl acetate = 1:1) afforded 28 as a white solid (377 mg, 69%). (Note: the regiochemistry of benzylation is uncertain, but this is inconsequential as the benzyl group is removed later. The ¹H NMR spectrum is complicated by the presence of Boc rotamers): $[\alpha]_{\rm D}^{23} = -8.8$ (c = 0.15, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.32 (5H, m), 5.75, 5.58 (2H, ABq, J = 18 Hz, $\Delta v = 31$ Hz), 5.02 (1H, m), 4.66 (1H, m), 2.15 (1H, m), 1.41 and 1.38 (each s, 9H total, rotamers), 0.93, 0.87, 0.85, and 0.47 (6H total, each d, J = 6.8 ppm, rotamers, diastereotopic Me groups); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 170.2, 166.7, 158.4, 156.0, 148.8, 144.8, 141.8, 136.2, 135.8, 134.0, 133.3, 130.7, 130.3,

129.4, 129.3, 128.5, 128.4, 128.3, 127.3, 121.2, 120.6, 120.3, 114.1, 113.9, 113.8, 108.9, 57.1, 51.6, 49.4, 32.6, 31.9, 22.4, 20.3, 19.3, 18.9, 17.9; HRMS (EI) calcd for $C_{17}H_{26}N_5O_2$ [M + H]⁺ 332.2067, found 332.2082.

(*S*)-1-(1-Benzyl-1H-tetrazol-5-yl)-2-methylpropan-1-amine (29). To a stirred solution of 28 (350 mg, 1.05 mmol) in DCM (5 mL) was added trifluoroacetic acid (0.3 mL), and stirring was continued for 72 h. After completion of the reaction, the excess solvent was removed by rotary evaporation. The residue was dissolved in ethyl acetate and washed with NaHCO₃ solution. The organic layer was dried over Na₂SO₄ and concentrated to afford 29 as a yellow oil (182 mg, 75%): $[\alpha]_D^{23} = -6.2$ (c = 0.1, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.27 (5H), 5.65 (2H, d, J = 1.2 Hz), 3.97(1H, d, J = 4.8 Hz), 2.06 (1H), 1.67 (2H, s), 0.84 (6H); ¹³C NMR (100 MHz, CD₃OD) δ (ppm) 170.1, 133.6, 129.4, 129.2, 129.1, 129.05, 128.4, 56.8, 54.2, 34.1, 19.2, 18.0; HRMS (EI) calcd for C₁₂H₁₇N₅ [M + H]⁺ 232.1562, found 232.1562.

(S)-2-Amino-N-(1-(1-benzyl-1H-tetrazol-5-yl)-2-methylpropyl)-6methylbenzamide (33). To a stirred solution of 6-methylisatoic anhydride (31) (400 mg, 2.25 mmol) in dry DMF (8 mL) were added DMAP (275 mg, 2.25 mmol) and 29 (520 mg, 2.25 mmol). The reaction mixture was stirred for 24 h at 100 °C, with progress being monitored by TLC using 50% ethyl acetate in hexanes. The reaction mixture was cooled to rt, then poured into ice water, and the product was extracted with ethyl acetate. The organic extract was dried over Na₂SO₄ and concentrated in vacuo. Flash chromatography of the residue (hexanes/ethyl acetate = 1:2) afforded 33 (420 mg, 52%): $[\alpha]_{D}^{23} = -28.3$ (c = 0.07, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.45 (1H, t, J = 8 Hz), 7.37 (5H), 7.07 (1H, d, J = 8 Hz), 6.93 (1H, d, J = 8 Hz), 6.12-5.82 (3H), 4.97 (1H, s), 2.62 (3H, s), 2.29(1H, m), 1.05 (3H, d, J = 6 Hz), 0.56 (3H, d, J = 6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 158.3, 155.9, 153.4, 143.5, 136.0, 134.3, 129.4, 129.2, 128.3, 127.2, 122.4, 51.5, 51.1, 32.2, 22.8, 19.2; HRMS (EI) calcd for $C_{20}H_{24}N_6O$ [M]⁺ 364.2012, found 364.2015.

(S)-tert-Butyl 2-((2-(((S)-1-(1-Benzyl-1H-tetrazol-5-yl)-2-methylpropyl)carbamoyl)-3-methylphenyl)carbamoyl)pyrrolidine-1carboxylate (35). To a stirred solution of N-Boc-L-proline (71 mg,

0.32 mmol) in pyridine (2 mL) under argon was added dropwise phosphorus oxychloride (0.2 mL, 2.0 mmol), maintaining the temperature at -10 °C. The reaction mixture was stirred for 1 h at -10 °C, followed by addition of a solution of 33 (116.5 mg, 0.32 mmol) in pyridine (1 mL). Stirring was continued for 8 h at -10 to -5 °C, then the mixture was added to ice-cooled 1 M aq HCl solution, and the product was extracted with ethyl acetate (3×10 mL). The combined extract was washed with brine, dried over Na2SO4, and concentrated in vacuo. Flash chromatography (hexanes/ethyl acetate = 1:1) afforded 35 as pale yellow gum (114 mg, 62%): $[\alpha]_{D}^{23} = -45.6$ (c = 0.08, CH₂Cl₂); ¹H NMR (400 MHz, CD₃OD) δ (ppm, rotamers) 7.69-7.84 (1H, m), 7.49-7.21 (6H, m), 7.05 (1H, d, J = 7.6 Hz), 6.0-5.78 (2H, m), 5.38-5.01 (1H, m), 4.45-4.22 (1H, m), 3.41 (2H, m), 2.40–1.81 (5H), 1.81–1.59 (3H), 1.40 (9H), 1.01, 0.45 (6H); ¹³C NMR (100 MHz, CD₃OD) δ (ppm) 177.1, 175.9, 170.5, 162.2, 160.5, 158.7, 139.9, 139.4, 138.6, 138.0, 133.8, 133.6, 133.2, 132.9, 132.7, 132.4, 132.0, 130.9, 130.6, 125.4, 124.7, 84.2, 65.3, 65.1, 64.8, 60.7, 56.2, 55.1, 36.7, 35.5, 35.0, 34.2, 33.9, 31.5, 28.2, 28.0, 27.4, 22.8, 22.6, 22.4, 22.1; HRMS (EI) calcd for C₃₀H₃₉N₇O₄ [M]⁺ 561.3064, found 561.3069.

(S)-tert-Butyl-2-(((3-methyl-2-(((S)-2-methyl-1-(1H-tetrazol-5-yl)propyl)carbamoyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (37). To a 10 mL three-neck reaction flask equipped with nitrogen inlet and outlet and reflux condenser was added 10 mL of dry methanol followed by ammonium formate (1.1 g, 18 mmol). The solution was degassed by passing N2 for 10 min, followed by addition of 50 mg of 10% Pd/C. After 5 min, amide 35 (100 mg, 0.18 mmol) in 1 mL of dry methanol was added, and the resulting mixture was stirred for 4 h at reflux temperature. The reaction progress was monitored by TLC using 80% ethyl acetate in hexanes. After completion of the reaction, the mixture was filtered through Celite and concentrated. Flash chromatography using 10% methanol in DCM to afforded 37 as a gum (60 mg, 71%): $[\alpha]_{D}^{23} = -59.2$ (c = 0.11, CH₂Cl₂); ¹H NMR (400 MHz, CD₃OD) δ (ppm, rotamers) 7.77, 7.72 (1H, d, J = 8.0 Hz), 7.29 (1H, t, J = 8.0 Hz), 7.08 (1H, d, J = 8.0 Hz), 5.35 (1H, m), 4.61, 4.20 (1H, m), 3.21 (2H, m), 2.40 (3H, s), 2.31-1.46 (5H), 1.41 (9H), 1.01 (6H). ¹³C NMR (100 MHz, CD₃OD) δ (ppm) 173.5, 169.7, 161.1, 154.8, 135.3, 134.5, 130.7, 129.1, 126.7, 121.4, 80.2, 61.1, 60.8, 59.7, 52.0, 31.7, 31.2, 30.7, 30.4, 29.9, 29.3, 27.6, 27.4, 24.1, 23.4, 18.7, 18.6, 17.7, 17.5; HRMS (EI) calcd for C₂₃H₃₃N₇O₄ [M]⁺ 471.2594, found 471.2562.

(S)-N-(3-Methyl-2-(((S)-2-methyl-1-(1H-tetrazol-5-yl)propyl)carbamoyl)phenyl)pyrrolidine-2-carboxamide (14). To a stirred solution of 37 (50 mg, 0.13 mmol) in 2 mL of dichloromethane was added 0.05 mL of TFA at room temperature. The reaction mixture was stirred for 72 h and then concentrated in vacuo. To remove acidic impurity, the product was dissolved in ice-cooled NaHCO3 solution and extracted with ethyl acetate $(2 \times 2 \text{ mL})$. The aqueous layer was acidified with 1 M aq HCl and extracted with 1-butanol $(3 \times 2 \text{ mL})$. The 1-butanol layer was collected, dried over Na2SO4, and concentrated in vacuo to afford 14 (yield 20 mg, 51%): $[\alpha]_{\rm D}^{23}$ = -91.2 (c = 0.015, 5% TFA in CH₃OH); mp 139–142 °C; ¹H NMR (400 MHz, CD₃OD) δ (ppm) 7.68 (1H, d, J = 8.0 Hz), 7.30 (1H, t, J= 8.0 Hz, 7.13 (1H, d, J = 8.0 Hz), 5.29 (1H, m), 4.70 (1H, m), 3.42-3.20 (2H, m), 2.40-2.20 (5H), 2.13-1.81 (3H), 0.99 (3H, d, J = 6.4 Hz), 0.95 (3H, d, J = 6.4 Hz); ¹³C NMR (150 MHz, DMSO- d_6) δ (ppm) 168.9, 168.1, 158.9, 135.1, 135.09, 131.6, 128.9, 126.4, 120.3, 60.7, 52.4, 46.6, 31.1, 30.9, 28.5, 24.0, 20.4, 19.5, 18.4; HRMS (ESI) calcd for $C_{18}H_{26}N_3O_2$ [M + H]⁺ 372.2142, found 372.2142.

(S)-2-Amino-N-(1-(1-benzyl-1H-tetrazol-5-yl)-2-methylpropyl)benzamide (**32**). Compound **32** was prepared as described for compound **33**, via ring opening of isatoic anhydride (**30**) by valine *N*benzyltetrazole (**29**): yield = 56%; $[\alpha]_D^{23} = -23.3$ (c = 0.1, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.35 (5H), 7.14 (1H, m), 6.93 (1H, d, *J* = 8.8 Hz), 6.61, 6.51 (2H, t, *J* = 8.8 Hz), 5.75 (2H), 5.45 (2H, br s), 5.41, 5.15 (1H, m), 2.35 (1H, m), 0.98, 0.41 (6H). The product was used in the next step without further characterization.

(S)-tert-Butyl-2-((2-(((S)-1-(1-benzyl-1H-tetrazol-5-yl)-2-methyl-propyl)carbamoyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (**34**): Yield 55%; $[\alpha]_{\rm D}^{23} = -39.6$ (c = 0.05, CH₂Cl₂); ¹H NMR (400

MHz, CD₃OD) δ (ppm, rotamer) 9.18, 8.92 (1H), 8.56, 8.41 (1H), 7.77 (1H, m), 7.45–7.31 (6H), 7.19 (1H), 5.95 (2H, m), 5.22, 4.98 (1H), 4.20 (1H), 3.42 (2H), 2.55–1.70 (5H), 1.40 (9H), 1.20, 1.02 (6H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.3, 175.6, 172.5, 169.4, 166.2, 156.1, 155.9, 154.5, 154.2, 140.2, 139.6, 134.3, 133.7, 133.2, 129.4, 129.3, 128.8, 128.5, 127.7, 123.0, 120.8, 118.0, 80.9, 80.4, 80.2, 62.8, 59.1, 57.1, 51.8, 51.5, 49.6, 46.9, 46.5, 33.2, 31.7, 31.6, 31.0, 29, 28.5, 24.6, 23.9, 23.8, 21.1, 19.7, 19.3, 18.9, 18.6. The product was used in the next step without further characterization.

(S)-tert-Butyl-2-((2-(((S)-2-methyl-1-(1H-tetrazol-5-yl)propyl)-carbamoyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate (**36** $): Yield 71%; <math>[\alpha]_D^{23} = -48.9$ (c = 0.04, CH₂Cl₂); ¹H NMR (400 MHz, CD₃OD) δ (ppm, rotamers) 8.29 (1H, d, J = 8.0 Hz), 7.64 (1H, d, J = 8.0 Hz), 7.46 (1H, t, J = 8.0 Hz), 7.18 (1H, t, J = 8.0 Hz), 5.22 (1H, m), 3.90 (1H, m), 2.99 (2H, m), 2.41–2.10 (2H, m), 1.99–1.60 (12H), 1.15–0.80 (6H); ¹³C NMR (100 MHz, CD₃OD) δ (ppm) 175.5, 172.8, 169.7, 157.5, 154.7, 138.5, 132.5, 128.2, 123.4, 121.1, 120.9, 120.5, 80.6, 80.2, 80.0, 62.6, 62.1, 59.3, 58.9, 51.5, 51.4, 46.3, 31.4, 31.1, 30.6, 30.3, 29.8, 27.6, 27.4, 24.0, 23.9, 23.4, 18.7, 18.5; HRMS (ESI) calcd for C₂₂H₃₂N₇O₄ [M + H]⁺ 458.2516, found 458.2512.

(*S*)-*N*-(2-(((*S*)-2-Methyl-1-(1*H*-tetrazol-5-yl)propyl)carbamoyl)phenyl)pyrrolidine-2-carboxamide (**13**): Yield 55%; mp 149–151 °C; ¹H NMR (400 MHz, CD₃OD) δ (ppm) 8.09 (1H, d, *J* = 8.0 Hz), 7.73 (1H, d, *J* = 8.0 Hz), 7.50 (1H, t, *J* = 8.0 Hz), 7.24 (1H, t, *J* = 8.0 Hz), 5.21 (1H, m), 4.50 (1H, m), 3.40 (2H, m), 2.58–2.38 (2H), 2.20– 1.98 (3H), 1.10 (3H, d, *J* = 6.0 Hz), 0.95 (3H, d, *J* = 6.0 Hz); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm) 170.7, 168.0, 159.1, 137.9, 133.1, 129.4, 125.9, 125.4, 123.8, 62.0, 52.4, 47.3, 47.2, 32.7, 30.5, 25.0, 19.6, 19.3; HRMS (ESI) calcd for C₁₇H₂₄N₇O₂ [M + H]⁺ 358.1991, found 358.1971.

General Aldol Reaction Procedure and Product Characterization. To a 3 mL reaction vial was taken up 20 mol % of catalyst in 0.1 mL of isopropyl alcohol followed by 550 mol % of water and 30 mol % of H_3PO_4 added to it (mol % is relative to 7-iodoisatin). The reaction mixture was stirred for 10 min at 4 °C after which time 2,2dimethyl-1,3-dioxan-5-one (0.8 mmol) was added. The reaction mixture was stirred for another 10 min at 4 °C followed by addition of 7-iodoisatin (0.2 mmol) and then stirred for 24 h to 6 days (monitored by TLC) at 4 °C. After completion of the reaction, the mixture was quenched with water and extracted into ethyl acetate, dried over Na₂SO₄, concentrated in vacuo, and separated by flash chromatography using 1:1 ethyl acetate/hexanes. Specific rotations of aldol products were not determined because they were not obtained optically pure.

(*S*)-3-((*S*)-2,2-Dimethyl-5-oxo-1,3-dioxan-4-yl)-3-hydroxy-7-iodoindolin-2-one (**3**): Isolated yield 75%; mp 198–200 °C; ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.38 (1H, s), 7.53 (1H, dd, *J* = 8.0, 1.2 Hz), 7.35 (1H, dd, *J* = 8.0, 1.2 Hz), 6.69 (1H, t, *J* = 8.0 Hz), 6.40 (1H, s), 4.62 (1H, d, *J* = 1.6 Hz), 4.03 (1H, dd, *J* = 17.6, 1.6 Hz), 3.90 (1H, d, *J* = 17.6 Hz), 1.43 (3H, s), 1.40 (3H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 207.0, 176.5, 146.8, 139.0, 130.5, 125.8, 124.2, 102.7, 101.3, 78.9, 75.5, 75.3, 67.0, 24.8, 23.7; HRMS (EI) calcd for C₁₄H₁₄INO₅ [M]⁺ 402.9917, found 402.9918.

(S)-7-Chloro-3-((S)-2,2-dimethyl-5-oxo-1,3-dioxan-4-yl)-3hydroxyindolin-2-one (**16**): Yield 74%; mp 169–170 °C; ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.77 (1H, s), 7.273 (2H), 6.89 (1H), 6.41(1H), 4.64 (1H, d, *J* = 1.6 Hz), 4.40 (1H, dd, *J* = 18.0, 1.6 Hz), 3.90 (1H, d, *J* = 18.0 Hz), 1.42 (3H, s), 1.40 (3H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 207.0, 176.7, 141.5, 131.2, 130.1, 124.9, 123.5, 114.3, 101.3, 78.7, 75.0, 67.0, 24.7, 23.7; HRMS (EI) calcd for C₁₄H₁₄ClNO₅ [M]⁺ 311.0516, found 311.0513.

(S)-7-Bromo-3-((S)-2,2-dimethyl-5-oxo-1,3-dioxan-4-yl)-3hydroxyindolin-2-one (17): Yield 70%; mp 185–186 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.52 (1H, br s), 7.38 (1H, d, *J* = 8.0 Hz), 7.23 (1H, d, *J* = 8.0 Hz), 6.85 (1H, t, *J* = 8.0 Hz), 4.48 (1H, d, *J* = 1.2 Hz), 4.22 (1H, dd, *J* = 18, 1.2 Hz), 3.98 (1H, d, *J* = 18 Hz), 1.32 (3H, s), 1.29 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 208.9, 175.2, 141.9, 133.3, 129.4, 124.6, 124.5, 123.4, 101.8, 101.7, 75.7, 75.3, 67.0,

The Journal of Organic Chemistry

66.9, 24.0, 23.6, 23.5, 23.4; HRMS (EI) calcd for $C_{14}H_{14}BrNO_5\ [M]^+$ 355.0055, found 355.0046.

(*S*)-6-Bromo-3-((*S*)-2,2-dimethyl-5-oxo-1,3-dioxan-4-yl)-3hydroxyindolin-2-one (**18**): Yield 72%; mp 184–185 °C; ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.49 (1H, s), 7.27 (1H, d, *J* = 8.0 Hz), 7.06 (1H, dd, *J* = 8.0, 1.6 Hz), 6.89 (1H, d, *J* = 1.6 Hz), 6.37 (1H, s), 4.64 (1H, 1.2 Hz), 4.02 (1H, dd, *J* = 16.0, 1.6 Hz), 3.90 (1H, d, *J* = 16.0 Hz), 1.45 (3H, s), 1.41 (3H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 205.0, 176.3, 143.1, 132.8, 131.7, 129.1, 113.6, 112.1, 101.4, 78.6, 74.3, 67.0, 24.6, 23.8; HRMS (EI) calcd for C₁₄H₁₄BrNO₅ [M]⁺ 355.0055, found 355.0047.

(5)-5-Bromo-3-((5)-2,2-dimethyl-5-oxo-1,3-dioxan-4-yl)-3hydroxyindolin-2-one (**19**): Yield 75%; mp 191–193 °C; ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.48 (1H), 7.33 (2H), 6.71 (1H, d, *J* = 8.0 Hz), 6.41 (1H, s), 4.64 (1H, s), 4.10 (1H, dd, *J* = 17.6, 1.6 Hz), 3.90 (1H, d, *J* = 17.6 Hz), 1.45 (3H, s), 1.41 (3H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 207.0, 176.8, 145.5, 128.7, 128.1, 124.7, 122.9, 112.9, 101.3, 78.7, 74.1, 67.0, 24.7, 23.8; HRMS (EI) calcd for C₁₄H₁₄BrNO₅ [M]⁺ 355.0055, found 355.0027.

(*S*)-*4*-*B*romo-3-((*S*)-2,2-*d*imethyl-5-oxo-1,3-*d*ioxan-4-yl)-3hydroxyindolin-2-one (**20**): Yield 75%; mp 190–192 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) 10.60 (1H, s), 7.12 (2H), 6.76 (1H, d, *J* = 8.0 Hz), 6.07 (1H, s), 4.99 (1H, s), 4.49 (1H, *J* = 22.0, 1.6 Hz), 4.40 (1H, d, *J* = 22.0 Hz), 1.26 (3H, s), 1.17 (3H, s); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm) 206.3, 178.5, 145.8, 132.3, 127.9, 126.5, 119.1, 100.8, 100.5, 79.5, 74.9, 68.0, 25.9, 23.3; HRMS (EI) calcd for C₁₄H₁₄BrNO₅ [M]⁺ 355.0055, found 355.0035.

Methods for Conversions Shown in Scheme 2. (S/R)-3-Hydroxy-3-((4R/S,5S/R)-5-hydroxy-2,2-dimethyl-1,3-dioxan-4-yl)-7iodoindolin-2-one (rac-21). To a stirred solution of racemic 3 (200 mg, 0.49 mmol; produced by aldol reaction of 4 with 6 in the presence of pyrrolidine as catalyst) in dry methanol (5 mL) was added NaBH₄ (9.26 mg, 0.25 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h then brought to 4 °C and stirred for another 1 h. After completion of the reaction, excess methanol was removed in vacuo. The reaction mixture was quenched with water and extracted with ethyl acetate, dried over Na2SO4, and concentrated to afford rac-21 (178 mg, 75%): mp 198–200 °C; ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.51 (1H, s), 7.52 (1H, dd, J = 8.0, 1.2 Hz), 7.33 (1H, dd, J = 8.0, 1.2 Hz), 6.78 (1H, t, J = 8.0 Hz), 6.41 (1H, s), 4.92 (1H, d, J = 1.6 Hz), 4.27 (1H, d, J = 1.6 Hz), 3.90 (1H, dt, J = 12.8, 1.6 Hz), 3.68 (1H, app. p, J = 1.6 Hz), 3.52 (1H, dd, J = 12.8, 1.6 Hz), 1.20 (3H, s), 1.12 (3H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 179.5, 146.0, 138.5, 133.9, 124.7, 124.4, 99.0, 78.3, 75.9, 75.4, 66.0, 63.2, 29.7, 19.2; HRMS (EI) calcd for $C_{14}H_{17}INO_5$ [M + H]⁺ 406.0151, found 406 0142

(S/R)-3-Hydroxy-3-((4R/S,5R/S)-5-hydroxy-2,2-dimethyl-1,3-dioxan-4-yl)-7-iodoindolin-2-one (rac-22). To a stirred solution of racemic 3 (100 mg, 0.25 mmol) in dry acetone was added NaBH(OAc)₃ at -15 °C. The reaction mixture was stirred for 2 h at -15 °C. After completion of the reaction, excess acetone was removed in vacuo. The reaction mixture was quenched with water and extracted with ethyl acetate; the organic extract was dried over Na₂SO₄ and concentrated to afford rac-22 as a gum (200 mg, 84%): ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.07 (1H, s), 7.52 (1H, dd, J = 7.6, 0.8 Hz), 7.30 (1H), 6.73 (1H, t, J = 7.2 Hz), 6.15 (1H, br s), 4.82 (1H, br s), 3.95 (1H, d, J = 6.0 Hz), 3.47–3.39 (2H), 3.17(1H), 1.33 (3H, s), 1.22 (3H, s). The splitting patterns are not clear, so we also ran the NMR in CDCl₃: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 10.06 1H, 7.50 (1H, dd, J = 8.0, 1.2 Hz), 7.28 (1H, dd, J = 8.0, 1.2 Hz), 6.70 (1H, t, J = 8.0 Hz), 3.93 (1H, d, J = 9.2 Hz), 3.43 (1H, ABX, $J_{AB} = 11.2$, J_{AX} = 5.6 Hz, $\Delta \nu$ = 25.2 Hz), 3.36 (1H, ABX, J_{AB} = 11.2, J_{BX} = 9.2 Hz, $\Delta \nu$ = 25.2 Hz), 3.15 (1H, ddd, J = 9.2, 9.2, 5.6 Hz), 1.30 (3H), 1.20 (3H); ^{13}C NMR (100 MHz, DMSO- $d_6)$ δ (ppm) 177.4, 146.5, 138.6, 131.7, 125.5, 124.0, 98.9, 77.6, 77.0, 75.2, 64.5, 65.7, 29.0, 19.8; HRMS (EI) calcd for C₁₄H₁₇INO₅ [M + H]⁺ 406.0151, found 406.0132.

(3S/R)-3-((4R/S,5R/S)-5-(Benzylamino)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxy-7-iodoindolin-2-one (rac-23a) and (S/R)-3-((4R/ S,5S/R)-5-(Benzylamino)-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxy-7-iodoindolin-2-one (rac-23b). To a stirred solution of racemic 3 (100 mg, 0.25 mmol) in dry DCM at 2 °C were added benzylamine

(0.035 mL, 0.3 mmol) and 4 Å molecular sieves. The mixture was stirred for 24 h, followed by addition of NaBH₂CN (48 mg, 0.75 mmol), and stirring was continued for 48 h at 2 °C. After completion of the reaction, the mixture was concentrated and purified by preparative TLC using 1:1 ethyl acetate and hexanes to afford the mixture of diastereomers rac-23a/b (52 mg, 42%): ¹H NMR of 1:1 mixture (400 MHz, CDCl₃) δ (ppm) 7.67 (1H), 7.42 (1H), 7.38–7.26 (5H), 6.89 (1H), 6.40 (1H), 5.04 (2H), 4.77-4.27 (3H), 3.80-3.58 (3H), 1.52, 1.35 (6H). Only compound rac-23b was obtained pure using preparative TLC after three solvent elutions: ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.54 (1H, dd, J = 8.0, 1.2 Hz), 7.26–7.14 (6H), 6.33 (1H, t, J = 8.0 Hz), 5.52 (1H, br s), 5.02 (1H, d, J = 16Hz), 4.51 (1H, d, J = 3.6 Hz), 4.11 (1H, d, J = 16 Hz), 3.85 (1H, dd, J = 13.6, 8.8 Hz), 3.82 (1H, dd, J = 13.6, 8.0 Hz), 3.55 (1H, dd, J = 6.8, 3.6 Hz), 1.27 (3H, s), 1.09 (3H, s); 13 C NMR (100 MHz, CDCl₃) δ (ppm) 174.7, 146.7, 139.1, 135.1, 130.6, 128.9, 127.8, 121.1, 118.5, 98.6, 88.0, 82.2, 69.2, 57.9, 51.8, 44.3, 27.9, 19.8; HRMS (ESI) calcd for $C_{21}H_{23}IN_2NaO_4 [M + Na]^+$ 517.0600, found 517.0595.

(S/R)-3-((S/R)-2,2-Dimethyl-5-oxo-1,3-dioxan-4-yl)-7-iodo-3-((trimethylsilyl)oxy)indolin-2-one (rac-24). To a stirred solution of racemic 3 (300 mg, 0.74) in dry DCM (10 mL) at -15 °C was added 2,6-lutidine (0.86 mL, 7.4 mmol). The mixture was stirred for 10 min, then cooled to -15 °C, followed by addition of trimethylsilyl trifluoromethanesulfonate (0.67 mL, 3.7 mmol). The reaction was stirred at -15 °C for 4 h and monitored by TLC (1:1, ethyl acetate/ hexanes) and then was quenched by addition of cold NaHCO3 solution at -15 °C. The mixture was extracted with DCM, washed with cold 5% citric acid solution, and concentrated to afford rac-24 (288 mg, 82%): ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.67 (1H, s), 7.72 (1H, dd, J = 8.0, 1.2 Hz), 7.53 (1H, dd, J = 8.0, 0.8 Hz), 6.66 (1H, t, J = 8.0 Hz), 5.85 (1H, s), 4.75(1H, d, J = 1.2 Hz), 4.13 (1H, d, J = 17.6 Hz), 4.02 (1H, d, J = 17.6 Hz), 1.57 (3H, s), 1.55 (3H, s), 0.01 (9H, s); ¹³C NMR (100 MHz, DMSO- d_6) δ (ppm) 168.1, 158.9, 135.1, 135.1, 131.6, 128.9, 126.4, 120.3, 119.0, 118.4, 60.7, 52.4, 46.6, 46.2, 31.1, 31.0, 24.3, 24.0, 20.1, 19.5, 18.4; HRMS (ESI) calcd for $C_{17}H_{22}INO_{5}Si [M + H]^{+} 476.0390$, found 476.0382.

(4R/S,5S/R)-4-((S/R)-7-Iodo-2-oxo-3-((trimethylsilyl)oxy)indolin-3yl)-2,2-dimethyl-1,3-dioxan-5-yl methanesulfonate (rac-25). Reduction of the ketone of racemic 24 with NaBH₄ was accomplished as described for the synthesis of 21 (yield 83%): ¹H NMR (400 MHz, $CDCl_3$) δ (ppm) 8.67 (1H, s), 7.63 (1H, dd, J = 8.0, 1.2 Hz), 7.30 (1H, dd, J = 8.0, 0.8 Hz), 6.88 (1H, t, J = 8.0 Hz), 4.84 (1H, s), 4.23(1H, d, J = 1.2 Hz), 4.1–3.9 (3H), 1.33 (3H), 1.21 (3H), 0.001(9H). Owing to its instability, the crude product was used in the next step without further purification or characterization. To a stirred solution of the alcohol (180 mg, mmol) in CH2Cl2 (8 mL) at 0 °C was added DMAP (463 mg, 3.8 mmol). After 10 min, the reaction mixture was cooled to -15 °C and methanesulfonyl chloride (0.15 mL, 1.9 mmol) was added dropwise. After 4 h, the reaction mixture was warmed to rt and stirred for 11 h. The reaction mixture was poured into ice-water and extracted with CH_2Cl_2 (3 × 10 mL). The combined organic layers were washed with brine (15 mL) and dried over MgSO₄. Evaporation of the solvent followed by column chromatography (hexanes/ethyl acetate, 2:1) afforded rac-25 (168 mg, 80%): ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.68 (1H, s), 7.73 (1H, dd, J = 8.0, 1.2 Hz), 7.54 (1H, dd, I = 8.0, 1.2 Hz), 6.93 (1H, t, I = 8.0 Hz), 5.68 (1H, s), 4.64(1H, d, *J* = 1.6 Hz), 4.55 (1H, d, *J* = 1.6 Hz), 4.30, 4.01 (2H, ABq, *J* = ^{13}C 18.0 Hz), 2.98 (3H, s), 1.49 (3H, s), 1.43 (3H, s), 0.008 (9H, s); NMR (100 MHz, DMSO-d₆) δ (ppm) 173.5, 144.0, 137.2, 128.9, 124.6, 122.3, 97.8, 77.1, 73.7, 73.5, 69.3, 61.5, 36.2, 27.4, 17.4, 0.00; HRMS (ESI) calcd for C₁₈H₂₆INO₇SSiNa [M + Na]⁺ 578.0136, found 578.0138

(S/R)-3-((4R/S,5R/S)-5-Azido-2,2-dimethyl-1,3-dioxan-4-yl)-3-hydroxy-7-iodoindolin-2-one (rac-26). To a stirred solution of rac-25 (130 mg, 0.24 mmol) in DMF (3 mL) were added 18-crown-6 (124 mg, 0.48 mmol) and NaN₃ (156 mg, 2.4 mmol). The reaction mixture was stirred under argon for 96 h at 100 °C, and progress was monitored by TLC (ethyl acetate/hexanes, 1:2). After completion of the reaction, the mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with water (3 ×

The Journal of Organic Chemistry

20 mL) to remove DMF. The organic layer was dried over Na₂SO₄. Evaporation of the solvent followed by column chromatography (hexanes/ethyl acetate, 2:1) of the crude residue afforded *rac*-**26** (69 mg, 67%): ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) 10.30 (1H, s), 7.55 (1H, dd, *J* = 8.0, 1.2 Hz), 7.35 (1H, dd, *J* = 8.0, 1.2 Hz), 6.78 (1H, t, *J* = 8.0 Hz), 4.09 (1H, m), 3.96 (1H, d, *J* = 8.0 Hz), 3.77 (1H, dd, *J* = 12.0, 4.0 Hz), 3.50 (1H, dd, *J* = 12.0, 5.6 Hz), 1.13 (3H, s), 1.08 (3H, s); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm) 177.5, 138.8, 132.6, 124.4, 124.3, 110.2, 100.0, 76.3, 75.6, 75.5, 62.6, 56.3, 27.0, 21.3; HRMS (ESI) calcd for C₁₄H₁₅IN₄NaO₄ [M + Na]⁺ 453.0036, found 453.0020.

Benzyl ((4R/S,5R/S)-4-((S/R)-3-Hydroxy-7-iodo-2-oxoindolin-3-yl)-2,2-dimethyl-1,3-dioxan-5-yl)carbamate (rac-5). To a stirred solution of rac-26 (40 mg, 0.09 mmol) in dry THF at 0 °C was added PMe₃ (1.0 M in THF 0.15 mL, 0.13 mmol). The reaction mixture was stirred at 0 °C for 4 h, followed by addition of CbzCl (25 μ L), and stirring was continued for 3 h at 0 °C. The reaction mixture was poured into ice-cooled water and extracted with ethyl acetate, and the organic layer was dried over Na₂SO₄ and concentrated. The product was purified by preparative TLC (ethyl acetate/hexanes, 2:3) to afford *rac*-**5** (35 mg, 69%): ¹H NMR (400 MHz, DMSO- d_6) δ (ppm) 10.07 (1H, br s), 7.51 (1H), 7.29 (5H), 6.98 (1H), 6.73 (1H), 6.15 (1H), 4.95 (2H, ABq, J = 8.0 Hz, $\Delta \nu = 16.2$ Hz), 4.13 (1H, d, J = 8.0 Hz), 3.54-3.09 (3H), 1.30 (3H, s), 1.22 (3H, s); ¹³C NMR (150 MHz, CDCl₃) δ (ppm) 176.9, 154.1, 144.4, 138.5, 133.2, 130.0, 129.8, 128.6, 125.1, 124.3, 79.6, 74.7, 73.1, 58.3, 52.4, 46.8, 26.1, 23.2; HRMS (ESI) calcd for C₂₂H₂₄IN₂O₆ [M + H]⁺ 539.0679, found 539.0674.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra for all new compounds, Xray data, HPLC data, and CD data for compound **3**. This material is available free of charge via the Internet at http:// pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: ajp4@case.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful to the Department of Chemistry, Case Western Reserve University, for financial support.

REFERENCES

(1) (a) For a compilation of reviews, see: List, B. *Chem. Rev.* 2007, 107, 543. (b) Coulthard, G.; Erab, W.; Aggarwal, V. K. *Nature* 2012, 489, 278. (c) Northrup, A. B.; Macmillan, D. W. *Science* 2004, 305, 1752.

(2) (a) Peddibhotla, S. Curr. Bioact. Compd. 2009, 5, 20. (b) Zhou, F.; Liu, Y. L.; Zhou, J. Adv. Synth. Catal. 2010, 352, 1381. (c) Shen, K.; Liu, X.; Lin, L.; Feng, X. Chem. Sci. 2012, 3, 327.

(3) (a) Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. *J. Antibiot.* **2000**, *53*, 105. (b) Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. *J. Org. Chem.* **2000**, *65*, 990.

(4) Kamano, Y.; Zhang, H.-P.; Ichihara, Y.; Kizu, H.; Komiyama, K.; Pettit, G. R. *Tetrahedron Lett.* **1995**, *36*, 2783.

(5) Suzuki, H.; Morita, H.; Shiro, M.; Kobayashi, J. Tetrahedron 2003, 59, 5307.

(6) Tang, Y.-Q.; Sattler, I.; Thiericke, R.; Grabley, S.; Feng, X.-Z. *Eur. J. Org. Chem.* **2001**, *261*, *7*.

(7) (a) Lin, S.; Yang, Z.-Q.; Kwok, B. H. B.; Koldobskiy, M.; Crews,
C. M.; Danishefsky, S. J. J. Am. Chem. Soc. 2004, 126, 6347.
(b) Albrecht, B. K.; Williams, R. M. Org. Lett. 2003, 5, 197. (c) Inoue,

M.; Sakazaki, H.; Fukuyama, H.; Hirama, M. Angew. Chem., Int. Ed. 2003, 42, 2654.

- (8) Takayama, H.; Shimizu, T.; Sada, H.; Harada, Y.; Kitajima, M.; Aimi, N. *Tetrahedron* **1999**, *55*, 6841.
- (9) (a) Pearson, A. J.; Panda, S. Org. Lett. 2011, 13, 5548.
 (b) Pearson, A. J.; Panda, S. Tetrahedron 2011, 67, 3969.

(10) (a) Monica, R.; Veerasamy, N.; Singh, V. K. *Tetrahedron Lett.* **2010**, *51*, 2157. (b) Ricci, A.; Bernardi, L.; Gioia, C.; Vierucci, S.; Robitzer, M.; Quignard, F. *Chem. Commun.* **2010**, *46*, 6288. (c) Liu, Y.;

Gao, P.; Wang, J.; Sun, Q.; Ge, Z.; Li, R. Synlett **2012**, 23, 1031. (11) (a) Cobb, A. I. A.; Shaw, D. M.; Ley, S. V. Synlett **2004**, 558.

(b) Torii, H.; Nakadai, M.; Ishihara, K.; Saito, S.; Yamamoto, H. Angew. Chem., Int. Ed. 2004, 43, 1983. (c) Hartikka, A.; Arvidsson, P. I. Tetrahedron: Asymmetry 2004, 15, 1831.

(12) Córdova, A.; Zou, W.; Dziedzic, P.; Ibrahem, I.; Reyes, E.; Xu, Y. *Chem.—Eur. J.* **2006**, *12*, 5383.

(13) Saito, S.; Yamamoto, H. Acc. Chem. Res. 2004, 37, 570.

(14) Berkessel, A.; Koch, B.; Lex, J. Adv. Synth. Catal. 2004, 346, 1141.

(15) Xue, F.; Zhang, S.; Liu, L.; Duan, W.; Wang, W. Chem.—Asian J. 2009, 4, 1664.

(16) Hamuro, Y.; Geib, S. J.; Hamilton, A. D. J. Am. Chem. Soc. 1996, 118, 7529.

(17) Evans, D. A.; Chapman, K. T.; Carreira, E. M. J. Am. Chem. Soc. 1988, 110, 3560.

(18) (a) Veenstra, S. J.; Kindermanb, S. S. Synlett 2001, 7, 1109.
(b) Williams, D. R.; Osterhout, M. H. J. Am. Chem. Soc. 1992, 110, 3560. (c) Williams, D. R.; Benbow, J. W.; Sattleberg, T. R.; Ihle, D. C. Tetrahedron Lett. 2001, 42, 8597.

(19) Enders, D.; Paleček, J.; Grondal, C. Chem. Commun. 2006, 655.
(20) Sureshbabu, V. V.; Naik, S. A.; Nagendra, G. Synth. Commun. 2009, 39, 395.